Janus Henderson Group PLC Affimed N.V. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.27 - $4.86 $2.25 Million - $4.83 Million	-992,984 Reduced 85.46%	168,886 $467,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $895,024 - $1.37 Million	242,554 Added 26.38%	1,161,870 $5.06 Million
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $1.47 Million - $1.93 Million	-273,048 Reduced 22.9%	919,316 $5.08 Million
Q3 2021 Nov 16, 2021	BUY	$5.54 - $7.51 $3.69 Million - $5 Million	665,656 Added 126.38%	1,192,364 $7.38 Million
Q2 2021 Aug 16, 2021	BUY	$7.78 - $11.4 $4.1 Million - $6 Million	526,708 New	526,708 $4.47 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.